Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 57.28 USD 1.38%
Market Cap: 2.8B USD
Have any thoughts about
Vericel Corp?
Write Note

Vericel Corp
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Vericel Corp
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Vericel Corp
NASDAQ:VCEL
Total Current Liabilities
$41.3m
CAGR 3-Years
30%
CAGR 5-Years
22%
CAGR 10-Years
13%
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$43.1B
CAGR 3-Years
15%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$11.7B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$20.3B
CAGR 3-Years
11%
CAGR 5-Years
14%
CAGR 10-Years
9%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$4B
CAGR 3-Years
28%
CAGR 5-Years
23%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.7B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
24%
No Stocks Found

Vericel Corp
Glance View

Market Cap
2.8B USD
Industry
Biotechnology

Vericel Corporation, nestled in the bustling hub of biomedical innovation in Cambridge, Massachusetts, has carved out a niche in the realm of advanced cell therapies. Founded in the late 1980s, the company initially focused on regenerative medicine but has since honed its expertise on the development and commercialization of cell-based treatments for patients with serious medical conditions. Vericel's journey is underpinned by its flagship product lines like MACI® and Epicel®, which illustrate its commitment to technological advancement and improving patient outcomes. MACI®, a matrix-applied autologous cultured chondrocyte technology, is designed to repair cartilage defects in the knee, often providing relief to those who suffer chronic pain from cartilage injuries. Epicel®, on the other hand, caters to patients with severe burns, utilizing a patient's own skin cells to regenerate skin and improve healing. These innovative solutions demonstrate Vericel's strategic pivot towards addressing niche, high-need areas within the orthopedic and burn treatment spaces. Vericel makes its revenue primarily through the sales of its proprietary treatments to hospitals and healthcare providers. The company's growth is closely tied to its ability to navigate the intricate regulatory landscapes associated with biologics, ensuring that its therapies meet the stringent requirements set forth by entities like the FDA. By targeting specific, high-impact markets with limited existing solutions, Vericel secures a competitive edge and commands significant pricing power, which enhances its financial performance. The company invests heavily in clinical trials and research to support and expand the use of its technologies, seeking indications for broader patient populations. Additionally, Vericel is continually working to optimize its manufacturing processes to scale its operations effectively without compromising the quality and efficacy of its treatments. Through strategic partnerships and a focus on innovation, Vericel is poised to leverage its scientific expertise to further entrench its position within the specialized markets it serves.

VCEL Intrinsic Value
31.18 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

What is Vericel Corp's Total Current Liabilities?
Total Current Liabilities
41.3m USD

Based on the financial report for Sep 30, 2024, Vericel Corp's Total Current Liabilities amounts to 41.3m USD.

What is Vericel Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
13%

Over the last year, the Total Current Liabilities growth was 15%. The average annual Total Current Liabilities growth rates for Vericel Corp have been 30% over the past three years , 22% over the past five years , and 13% over the past ten years .

Back to Top